Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.1%

5 terminated out of 62 trials

Success Rate

78.3%

-8.2% vs benchmark

Late-Stage Pipeline

6%

4 trials in Phase 3/4

Results Transparency

28%

5 of 18 completed with results

Key Signals

5 with results78% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (16)
P 1 (9)
P 2 (11)
P 3 (3)
P 4 (1)

Trial Status

Completed18
Recruiting16
Unknown10
Active Not Recruiting7
Terminated5
Withdrawn4

Trial Success Rate

78.3%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (62)

Showing 20 of 20 trials
NCT04428736CompletedPrimary

Evaluating Cascade Communication Methods

NCT06972719Not ApplicableRecruitingPrimary

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

NCT06395519Phase 1Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

NCT01608074Not ApplicableActive Not RecruitingPrimary

Radical Fimbriectomy for Young BRCA Mutation Carriers

NCT05694715Phase 1Recruiting

Combination Therapy in Cancers With Mutations in DNA Repair Genes

NCT03351803Active Not RecruitingPrimary

BRCA Founder OutReach (BFOR) Study

NCT04780945Phase 2Terminated

Functional Analysis of BRCAness

NCT06177171Phase 1RecruitingPrimary

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

NCT04150042Phase 1Recruiting

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

NCT05498272Phase 2Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

NCT03685331Phase 1Completed

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT06380660Phase 1Recruiting

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

NCT05410951Active Not Recruiting

LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients

NCT06201234Phase 2Recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

NCT07253051RecruitingPrimary

BRCA Mutation Carriers' Platform a Multicenter Study

NCT03702309Recruiting

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

NCT05420064Not ApplicableRecruitingPrimary

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

NCT03544983Not ApplicableEnrolling By InvitationPrimary

Genetic Education in BRCA Families

NCT04499534Active Not RecruitingPrimary

BRCA1/2 Flu Vaccine

NCT04613440Not ApplicableRecruitingPrimary

FaCT Trial (Facilitated Cascade Testing Trial)

Scroll to load more

Research Network

Activity Timeline